China Resources Pharmaceutical Group Limited
HKEX:3320.HK
5.55 (HKD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 270,397.302 | 254,106.366 | 236,806.169 | 200,423.023 | 204,453.869 | 189,689.107 | 172,532.204 | 156,705.203 | 146,568.105 | 135,749.18 | 116,950.696 |
Cost of Revenue
| 227,030.95 | 214,971.606 | 201,425.883 | 168,129.162 | 170,436.179 | 154,758.728 | 144,256.056 | 132,596.104 | 123,369.243 | 114,259.158 | 96,801.611 |
Gross Profit
| 43,366.352 | 39,134.76 | 35,380.286 | 32,293.861 | 34,017.69 | 34,930.379 | 28,276.148 | 24,109.099 | 23,198.862 | 21,490.022 | 20,149.085 |
Gross Profit Ratio
| 0.16 | 0.154 | 0.149 | 0.161 | 0.166 | 0.184 | 0.164 | 0.154 | 0.158 | 0.158 | 0.172 |
Reseach & Development Expenses
| 0 | 2,089.518 | 1,688.551 | 1,317.964 | 1,154.293 | 1,039.28 | 908.176 | 789.416 | 781.144 | 944.794 | 730.617 |
General & Administrative Expenses
| 6,328.166 | 6,478.584 | 6,227.647 | 5,563.152 | 5,203.768 | 4,703.606 | 4,201.737 | 3,882.186 | 3,844.892 | 4,246.773 | 3,673.505 |
Selling & Marketing Expenses
| 18,909.898 | 19,033.096 | 17,530.7 | 16,029.445 | 19,188.523 | 18,340.88 | 13,868.785 | 10,947.479 | 10,111.546 | 8,800.154 | 8,423.115 |
SG&A
| 25,238.064 | 26,232.763 | 24,442.889 | 22,505.345 | 24,838.678 | 23,134.309 | 18,115.864 | 14,829.665 | 13,956.438 | 13,046.927 | 12,096.62 |
Other Expenses
| 0 | -1,726.747 | -1,399.833 | -558.491 | 706.1 | 467.245 | 451.395 | 311.619 | -211.8 | 43.571 | 304.302 |
Operating Expenses
| 30,442.16 | 28,322.281 | 26,131.44 | 23,823.309 | 25,992.971 | 23,269.589 | 17,877.498 | 14,308.447 | 13,287.774 | 13,046.927 | 12,096.62 |
Operating Income
| 11,920.685 | 10,812.479 | 9,248.846 | 8,470.552 | 8,024.719 | 10,444.22 | 9,287.495 | 8,322.932 | 7,879.267 | 8,851.069 | 8,513.905 |
Operating Income Ratio
| 0.044 | 0.043 | 0.039 | 0.042 | 0.039 | 0.055 | 0.054 | 0.053 | 0.054 | 0.065 | 0.073 |
Total Other Income Expenses Net
| -2,040.458 | -2,451.398 | -2,375.831 | -2,507.661 | -3,797.831 | -3,693.846 | -2,503.002 | -1,121.502 | -1,837.636 | -3,315.34 | -3,112.107 |
Income Before Tax
| 9,880.227 | 9,467.069 | 8,094.835 | 6,868.656 | 6,499.151 | 9,182.477 | 8,582.348 | 8,042.665 | 8,050.295 | 6,922.773 | 6,912.913 |
Income Before Tax Ratio
| 0.037 | 0.037 | 0.034 | 0.034 | 0.032 | 0.048 | 0.05 | 0.051 | 0.055 | 0.051 | 0.059 |
Income Tax Expense
| 2,105.224 | 2,012.402 | 1,761.026 | 1,751.867 | 1,541.765 | 1,610.153 | 1,715.482 | 2,074.576 | 1,968.061 | 1,430.902 | 1,458.286 |
Net Income
| 3,854.247 | 3,500.27 | 3,080.673 | 2,778.656 | 3,286.419 | 4,037.89 | 3,483.036 | 2,821.41 | 2,850.076 | 2,645.94 | 2,639.517 |
Net Income Ratio
| 0.014 | 0.014 | 0.013 | 0.014 | 0.016 | 0.021 | 0.02 | 0.018 | 0.019 | 0.019 | 0.023 |
EPS
| 0.68 | 0.66 | 0.6 | 0.52 | 0.52 | 0.64 | 0.55 | 0.57 | 0.62 | 0.43 | 0.43 |
EPS Diluted
| 0.68 | 0.66 | 0.6 | 0.52 | 0.52 | 0.64 | 0.55 | 0.57 | 0.62 | 0.43 | 0.43 |
EBITDA
| 15,430.904 | 15,473.212 | 11,945.779 | 12,465.982 | 12,576.399 | 13,656.341 | 10,739.21 | 9,950.79 | 9,146.737 | 8,324.396 | 7,719.787 |
EBITDA Ratio
| 0.057 | 0.055 | 0.051 | 0.054 | 0.051 | 0.063 | 0.062 | 0.061 | 0.062 | 0.075 | 0.083 |